IRLAB Therapeutics: Pirepemat Ph 2b study fully enrolled - ABG

>100 patients enrolled
Reduction of falls in overall study population
Topline data at the end of Q1'25


React-PD fully enrolled

Today IRLAB announced that its Ph 2b study testing pirepemat for the prevention of falls in Parkinson's disease (React-PD study) achieved the milestone of full recruitment. More than 100 patients are enrolled now, which is considered sufficient to show a potential treatment effect. Blinded data from patients that finished the study showed that the number of falls in the overall patient population (i.e. placebo and active treatment arms) are reduced by one third. Importantly, the company expects topline results at the end of Q1'25, in line with previous guidance.